Cerebral amyloid angiopathy

3 total trials MedDRA PT

Filter these 3 trials by phase, country, sponsor and more.

Open in Search →

Safety, Tolerability and Efficacy of NPI-001 (AT-001) in Patients with Hereditary Cystatin C Amyloid Angiopathy (HCCAA) Not authorised

2023-503969-36-00 4 "Hereditary Cystatin C Amyloid Angiopathy (HCCAA)"
A Study to Evaluate the Efficacy, Safety and Tolerability of ALN-APP in Patients with Cerebral Amyloid Angiopathy (CAA) Recruitment ended

2023-510137-29-01 4 2025-04-09 "Cerebral Amyloid Angiopathy (CAA) is a neurological conditio"
Safety, Tolerability and Efficacy of NPI-001 (AT-001) in Patients with Hereditary Cystatin C Amyloid Angiopathy (HCCAA) Recruitment ended

2023-503969-36-01 4 2024-03-26 "Hereditary Cystatin C Amyloid Angiopathy (HCCAA)"

Showing 1–3 of 3 trials